CJC-1295 No DAC Research Focus Considerations

CJC-1295 No DAC is a research-use-only peptide — a modified fragment of growth hormone-releasing hormone, frequently written in the literature as modified GRF (1-29) — that does not carry the drug affinity complex found on the DAC-modified version. For a business buyer, the considerations that actually matter reduce to three: confirm identity and purity by named analytical methods on the specific lot you are purchasing, confirm the certificate of analysis is published rather than sold on request, and confirm the compound is labeled and supplied for laboratory research use only. Everything else in a sourcing decision sits downstream of those three checks.

The rest of this page covers what the DAC distinction means chemically, how to describe the compound to your own customers without overstating the research, what a credible COA has to show, and the compliance questions that belong with your attorney rather than with a supplier.

The DAC distinction, in plain chemistry

CJC-1295 exists in the research supply market in two forms, and they are not the same molecule. The DAC version carries a drug affinity complex — a chemical group designed to bind reversibly to serum albumin, which research describes as substantially extending the time the peptide remains in circulation. Strip that complex off and you have the No DAC form: the same tetrasubstituted GHRH (1-29) backbone, without the albumin-binding element.

The practical consequence discussed in the literature is persistence. Studies indicate the DAC-modified analog was engineered for prolonged plasma presence, while the No DAC form behaves as a short-acting GHRH analog closer in profile to native GHRH fragments. That is the entire basis of the distinction, and it is why research groups select one over the other rather than treating them as substitutes.

For a catalog, this matters in two ways. First, the two forms are separate SKUs with separate COAs and separate handling — never merge them in product copy or in a spreadsheet. Second, the No DAC form is the one most commonly requested by buyers whose customers are running short-window signaling work, so demand patterns for the two rarely track together. If a supplier's site blurs the two, or lists 'CJC-1295' with no DAC designation at all, that is a sign the catalog was built by a marketer rather than by anyone reading the COAs.

Describing the compound without outrunning the evidence

The research on GHRH analogs is real, ongoing, and genuinely interesting — and it is also preclinical, mechanistic, and specific in scope. Research suggests GHRH analogs act on pituitary GHRH receptors to influence growth hormone secretion patterns; studies report differences in secretion profile between short-acting and long-acting analogs. That is the honest ceiling of what the science supports, and it is where compound descriptions should stop.

What that means for a reseller building product pages: describe the pathway, cite the class of research, and hedge it properly. 'Research suggests', 'studies report', 'investigated for its role in' are defensible. Anything that describes an outcome for a person is not — and it converts a research-chemical listing into an unapproved drug claim, which is a regulatory problem your supplier cannot solve for you.

These compounds are not FDA-approved drugs and are not for human consumption. Real Peptides supplies them for laboratory research use only, and the same framing should carry through any catalog that resells them. Buyers who inherit a supplier's overstated copy inherit the exposure with it.

Where it sits alongside related compounds in a catalog

Buyers rarely order a single short-chain GHRH analog in isolation. CJC-1295 No DAC is typically stocked next to other compounds in the growth-factor and signaling category, because research groups comparing secretion pathways want more than one reference point on the shelf.

That has a real operational implication: your fill rate on the category matters more than your price on any one SKU. A supplier who carries the No DAC form but is chronically out of stock on the adjacent compounds forces your customers to split orders, and split orders are where reseller relationships quietly die. When you evaluate a wholesale catalog, look at category depth and at how long individual SKUs stay listed, not just at the tier sheet.

The second implication is documentation consistency. If one compound in a category has a published lot-specific COA and the next has a generic 'typical analysis' PDF from 2019, the supplier's testing program is uneven — and you will find out which SKU was the weak one at the worst possible moment.

Reading a certificate of analysis on a short-chain peptide

A COA is the only part of a peptide purchase you can actually verify yourself. Purity percentages printed on a product page are marketing; a lot-specific document naming the method is evidence. Here is the difference between a COA that means something and one that does not.

That last row separates suppliers more cleanly than anything else in the industry. Charging for a COA, or releasing it only to closed accounts, inverts the purpose of the document — testing exists so a buyer can check before committing, not after. Whatever you conclude about any particular supplier, make pre-purchase COA access a non-negotiable line in your own vetting process.

One more point specific to short-chain peptides: purity assays measure the peptide content of the material, and related peptide impurities — truncated or deletion sequences from synthesis — are the realistic failure mode, not gross adulteration. That is precisely why the HPLC trace matters more than the headline figure. A trace shows you what the impurity profile looks like; a percentage tells you nothing about its shape.

Handling and inventory questions to settle before you order

Lyophilized peptides are shipped and stored as dry powder, and the handling questions a buyer should resolve upfront are about the chain of custody, not about preparation. Ask how material is packed for transit, how it is stored before it ships, and what the supplier's policy is when a shipment is delayed or arrives compromised. Ask whether the lot you receive will match the lot whose COA you reviewed. Ask what the labeled shelf reference is for the specific SKU, and get that in writing rather than inferring it from a forum post.

On preparation: Real Peptides does not provide reconstitution, dosing, or administration guidance for any compound, because these are research-use-only materials and that guidance would be inappropriate regardless of who asked. The only framework worth understanding as a buyer is concentration arithmetic — a vial is labeled by total peptide mass, and concentration is simply mass divided by volume, expressed as mg per mL. That is the entire scope of what a supplier should be explaining, and it is where this page stops as well. Research protocols are the responsibility of the qualified investigator, and any supplier volunteering more than that should worry you.

Compliance questions that belong with your attorney

This section is informational and is not legal advice. The framework below is a list of questions to raise with your own counsel and your state board — not a set of conclusions you can act on.

If you are a med spa, clinic, telehealth company, or reseller considering research compounds in your catalog, the questions worth putting in front of an attorney generally include: How does your state characterize the resale of research-use-only materials, and does your existing license touch that activity at all? What labeling and record-keeping obligations attach to products you resell under your own brand versus resell as-supplied? What does your professional board expect of you when a research chemical appears anywhere in your business, even outside your clinical scope? How do your marketing claims interact with federal rules on unapproved products, and who reviews your copy before it publishes? What does your insurance actually cover?

None of those has a single national answer, and anyone who gives you one confidently is guessing. Requirements vary by state and by license type, positions shift, and the only durable approach is to get a written opinion from counsel who knows your jurisdiction and your business model. A supplier's role is to give you verifiable documentation on what is in the vial. Your compliance posture is yours.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around documentation that a buyer can check independently, before spending anything.

Every compound in the catalog, including CJC-1295 No DAC 10mg, is supplied at 99%+ HPLC purity. Each batch goes through 7-panel testing, and the certificates of analysis are published — a prospective partner can read the lab results for a SKU before opening an account, rather than being asked to trust a percentage on a product page. COAs are never sold separately and never withheld until after purchase.

Wholesale pricing tiers are disclosed rather than quoted case by case behind an inquiry form, so partners can model landed cost against their own category strategy without a sales call. Fulfillment is handled in the US, with orders shipping in 5 to 7 days. Onboarding is a 3-step wholesale application: submit business details, get reviewed for program fit, and receive tier access on approval.

All compounds are supplied for laboratory research use only. Real Peptides does not provide dosing, reconstitution, or administration guidance, and does not supply or pair ancillary items with compounds.

The path from here

If you operate a business that stocks research compounds and you have reviewed the published COAs for the SKUs you care about, the next step is the Wholesale Partner Program application — business details, a fit review, and tier access on approval. Bring your own compliance questions to your attorney first; bring your catalog questions to the program.

Buyers building depth in this category can review the broader growth factor and tissue signaling research collection, compare the No DAC form against related compounds such as Ipamorelin 10mg and Tesamorelin 10mg, or start with the popular peptides list to see which SKUs move most consistently across partner catalogs.